US Stock Insider Trading | Phreesia disclosed 1 insider transaction on February 17

2026-02-20 03:09:20

On February 17, 2026, Phreesia (PHR) disclosed one insider transaction. Executive Linetsky David purchased 1,500 shares on July 15, 2025.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 17, 2026	Executive	Linetsky David	July 15, 2025	Buy	1500	26.73	40,100
February 2, 2026	Director	CAHILL EDWARD L, Goldstein Lainie, Munson Gillian	January 30, 2026	Buy	2232	13.43	30,000
January 20, 2026	Executive	Linetsky David	January 15, 2026	Sell	1743	16.38	28,500
January 20, 2026	Executive	Gandhi Balaji	January 16, 2026	Sell	4687	16.36	76,700
January 20, 2026	Executive	Hoffman Allison C	January 15, 2026	Sell	1106	16.38	18,100
January 20, 2026	Executive	Hoffman Allison C	January 16, 2026	Sell	3995	16.36	65,300
January 20, 2026	Director	Indig Chaim	January 16, 2026	Sell	9595	16.36	156,900
January 20, 2026	Director	Indig Chaim	January 15, 2026	Sell	3038	16.38	49,800
January 20, 2026	Executive	Gandhi Balaji	January 15, 2026	Sell	975	16.38	16,000
January 20, 2026	Executive	Linetsky David	January 16, 2026	Sell	6038	16.36	98,800

[Company Information]

Phreesia, Inc. was incorporated in 2005 under Delaware law. The company is a leading provider of comprehensive solutions that transform healthcare by engaging patients in their care and enabling healthcare provider organizations to optimize operations, increase profitability, and improve clinical care. Through its SaaS-based Phreesia platform, the company offers a robust suite of solutions to manage patient admission processes and integrated payment solutions for secure patient payments. The platform also provides engagement channels for life sciences companies to communicate targeted and direct messages with patients.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes